[Atherogenic lipoprotein remnants in humans].
Remnant lipoproteins (RLPs) are the lipolytic product of triglycerides transported by very low density lipoproteins (VLDL) of hepatic and intestinal origin and intestinal chylomicrons. Lipoprotein lipase activity hydrolyse triglycerides in several steps, producing heterogeneous particles. Fasting plasma concentration in normolipidemic subjects is low, but it increases in post-prandial states. Genetic alterations in Apo-E subtypes increases RLPs plasma concentration and produce dyslipoproteinemia phenotype. RLPs atherogenicity depends on their role as endothelial injuring factors, their impaired recognition by lipoprotein receptors, and their susceptibility to oxidative stress. They also promote the circulation of molecular adhesion molecules, the internalization in subendothelial macrophages via scavenger receptors and the accumulation in foam cells, all of them early mechanisms of atheromatosis. RLPs metabolism has been a subject of controversial studies. Their origin from different lipoproteins may explain their structural heterogeneity, therefore increasing the methodological difficulties to include RLPs in the atherogenic lipoprotein profile in the epidemiological studies of the field. Last advances on metabolism of RLPs and their emergent clinical role justifies an up dated revision of RLPs.
Wikinski
Regina
R
Instituto de de Fisiopatología y Bioquímica Clínica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Lipoproteínas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires. rwikinski@fibertel.com.ar
Schreier
Laura E
LE
Berg
Gabriela A
GA
Brites
Fernando D
FD
López
Graciela
G
González
Ana I
AI
Zago
Valeria
V
D050197:Atherosclerosis / Q000097:blood*; D053298:Chylomicron Remnants / Q000097:blood; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood
D053298:Chylomicron Remnants; D008074:Lipoproteins; D008077:Lipoproteins, LDL